In situ redox functionalization of composite electrodes for high power-high energy electrochemical storage systems via a non-covalent approach

The growing demand for new global resources of clean and sustainable energy emerges as the greatest challenge in today\u27s society. For numerous applications such as hybrid vehicles, electrochemical storage systems simultaneously require high energy and high power. For this reason, intensive researches focus on proposing alternative devices to conventional Li battery and supercapacitors. Here, we report a proof of concept based on non-covalent redox functionalization of composite electrodes that may occur either during the calendar life or during the device functioning. The active material, a multi-redox pyrene derivative, is initially contained in the electrolyte. No additional benchmarking step is therefore required, and it can, in principle, be readily applied to any type of composite electrode (supercapacitors, battery, semi-solid flow cell etc.). Accordingly, a practical carbon fiber electrode that is 10 mg cm(-2) loaded can deliver up to 130 kW kg(electrode)(-1) and 130 Wh kg(electrode)(-1) with negligible capacity loss over the first 60 000 charge/discharge cycles

New Concept to Boost Energy and Power Peformance of Practical Electrochemical Devices

International audienc

New concept and electrochemistry of in situ non-covalent immobilization of redox molecules for energy storage applications

International audienc

Netrin-1 expression is an independent prognostic factor for poor patient survival in brain metastases

The multifunctional molecule netrin-1 is upregulated in various malignancies and has recently been presented as a major general player in tumorigenesis leading to tumor progression and maintenance in various animal models. However, there is still a lack of clinico-epidemiological data related to netrin-1 expression. Therefore, the aim of our study was to elucidate the association of netrin-1 expression and patient survival in brain metastases since those constitute one of the most limiting factors for patient prognosis. We investigated 104 brain metastases cases for netrin-1 expression using in-situ hybridization and immunohistochemistry with regard to clinical parameters such as patient survival and MRI data. Our data show that netrin-1 is strongly upregulated in most cancer subtypes. Univariate analyses revealed netrin-1 expression as a significant factor associated with poor patient survival in the total cohort of brain metastasis patients and in sub-entities such as non-small cell lung carcinomas. Interestingly, many cancer samples showed a strong nuclear netrin-1 signal which was recently linked to a truncated netrin-1 variant that enhances tumor growth. Nuclear netrin-1 expression was associated with poor patient survival in univariate as well as in multivariate analyses. Our data indicate both total and nuclear netrin-1 expression as prognostic factors in brain metastases patients in contrast to other prognostic markers in oncology such as patient age, number of brain metastases or Ki67 proliferation index. Therefore, nuclear netrin-1 expression constitutes one of the first reported molecular biomarkers for patient survival in brain metastases. Furthermore, netrin-1 may constitute a promising target for future anti-cancer treatment approaches in brain metastases